Cell Death Discovery (Apr 2024)

METTL14 promotes neuroblastoma formation by inhibiting YWHAH via an m6A-YTHDF1-dependent mechanism

  • Jianwei Wang,
  • Hongli Yin,
  • Gen Li,
  • Di Wu,
  • Yunyun Xu,
  • Yanling Chen,
  • Xiaodong Wang,
  • Yujiao Xing,
  • Ting Zhang,
  • Danhong Fei,
  • Pengcheng Yang,
  • Fang Fang,
  • Yanfang Tao,
  • Xiaolu Li,
  • Juanjuan Yu,
  • Yang Yang,
  • Zhiheng Li,
  • Lei Shi,
  • Zimu Zhang,
  • Jian Pan

DOI
https://doi.org/10.1038/s41420-024-01959-8
Journal volume & issue
Vol. 10, no. 1
pp. 1 – 15

Abstract

Read online

Abstract Neuroblastoma (NB) is a common childhood tumor with a high incidence worldwide. The regulatory role of RNA N6-methyladenosine (m6A) in gene expression has attracted significant attention, and the impact of methyltransferase-like 14 (METTL14) on tumor progression has been extensively studied in various types of cancer. However, the specific influence of METTL14 on NB remains unexplored. Using data from the Target database, our study revealed significant upregulation of METTL14 expression in high-risk NB patients, with strong correlation with poor prognosis. Furthermore, we identified ETS1 and YY1 as upstream regulators that control the expression of METTL14. In vitro experiments involving the knockdown of METTL14 in NB cells demonstrated significant inhibition of cell proliferation, migration, and invasion. In addition, suppressing METTL14 inhibited NB tumorigenesis in nude mouse models. Through MeRIP-seq and RNA-seq analyses, we further discovered that YWHAH is a downstream target gene of METTL14. Mechanistically, we observed that methylated YWHAH transcripts, particularly those in the 5′ UTR, were specifically recognized by the m6A “reader” protein YTHDF1, leading to the degradation of YWHAH mRNA. Moreover, the downregulation of YWHAH expression activated the PI3K/AKT signaling pathway, promoting NB cell activity. Overall, our study provides valuable insights into the oncogenic effects of METTL14 in NB cells, highlighting its role in inhibiting YWHAH expression through an m6A-YTHDF1-dependent mechanism. These findings also suggest the potential utility of a biomarker panel for prognostic prediction in NB patients.